REPL
What one share of Replimune Group holds
Biological Products, (No Diagnostic Substances)
We are a clinical-stage biotechnology company committed to applying our leading expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through our novel oncolytic immunotherapies. Our proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer.
Replimune Group’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$3.15 |
|---|---|
| Capex (buildings and equipment) | $0.02 |
| Free cash flow | −$2.98 |
| Cash and investments | $2.21 |
| Debt | $1.29 |
| Book value | $1.26 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2017 | — | −$1.55 | $0.05 | −$1.47 | — | −$2.32 |
| 2018 | — | −$3.96 | $0.03 | −$3.24 | — | −$5.61 |
| 2019 | — | −$1.33 | $0.11 | −$1.21 | — | $4.35 |
| 2020 | — | −$1.54 | $0.19 | −$1.96 | — | $5.01 |
| 2021 | — | −$1.75 | $0.05 | −$1.38 | — | $10.71 |
| 2022 | — | −$2.26 | $0.04 | −$1.62 | — | $8.69 |
| 2023 | — | −$2.99 | $0.04 | −$2.24 | — | $9.80 |
| 2024 | — | −$3.24 | $0.09 | −$2.87 | — | $6.10 |
| 2025 | — | −$3.07 | $0.08 | −$2.47 | — | $5.39 |
| 2026 | — | −$3.38 | $0.05 | −$3.07 | — | $2.01 |